SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from two Phase 2 studies designed to identify the hospitalized patient population suffering from COVID-19-induced pneumonia and respiratory depression likely to respond to treatment with oral Abivertinib. Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) as well as Bruton's tyrosine kinase (BTK). Abivertinib irreversibly binds to the BTK receptor, preventing the phosphorylation of the receptor. Due to this effect, it has shown potent immunomodulatory activities in vitro with potent inhibition of key pro-inflammatory cytokine production, including IL-1 beta, IL-6 and TNF-alpha. These cytokines are associated with acute respiratory distress syndrome (ARDS), and with cytokine release syndrome (CRS) or cytokine storm, and COVID-19 disease progression with poor outcomes in patients.

Originally posted here:
UPDATE  – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the company will report third quarter 2021 financial results on Wednesday, November 10, 2021. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

See original here:
TELA Bio to Announce Third Quarter 2021 Financial Results

Daix (France), Long Island City (New York, United States), October 27, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the design of a proof-of-concept Phase IIa combination trial with its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin in patients with T2D and non-cirrhotic NASH.

See the original post here:
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and...

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.

Go here to read the rest:
SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals

Go here to see the original:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

Alan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEO Alan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEO

Go here to read the rest:
Checkmate Pharmaceuticals Announces CEO Transition

DURHAM, N.C., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November 9, 2021.

See the rest here:
Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call on Wednesday, November 10, 2021.

See the original post:
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesday, November 2, 2021. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics’ performance for the third quarter of 2021.

Read the rest here:
Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its business update and financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.

Read more:
PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

- All Stockholder Proposals Were Approved -

Read the original:
Greenrose Acquisition Corp. Stockholders Approve Business Combination

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first patient received their first dose on October 27, 2021.

Here is the original post:
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2021 after the market closes on Wednesday, November 3, 2021.

Continue reading here:
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the previously announced, proposed primary and secondary public offering. With our strong balance sheet, we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our stockholders. We are well capitalized, with cash and cash equivalents of $225 million as of September 30, 2021, which we believe, together with the drawdown of the remaining $100 million under our term loan facility, will be sufficient to fund our operations into mid-2023.

Read the original post:
Phathom Pharmaceuticals Withdraws Public Offering

NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATION28 OCTOBER 2021, 07:00 CEST

Follow this link:
MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

See more here:
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

– U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) –

See the rest here:
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update

Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November

Read the original:
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Paris, October 28, 2021

Read more from the original source:
Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)

Oslo, Norway, 28th of October 2021

Link:
Vistin Pharma ASA: Third quarter 2021 financial results